[1]
|
Zhang, L., Fang, W., Wang, L., Wang, W., Liu, B., Jian, L., Chen, M., Qiang, H., Liao, Y. and Yu, X. (2012) Prevalence of Chronic Kidney Disease in China: A Cross-Sectional Survey. The Lancet, 380, 214-214.
https://doi.org/10.1016/S0140-6736(12)60033-6
|
[2]
|
傅晓岑, 任红, 陈楠. 肾性贫血的治疗研究[J]. 中国血液净化, 2022, 21(1): 6-9.
|
[3]
|
王莉君, 袁伟杰. 关于肾性贫血治疗相关指南与共识回顾[J]. 中国血液净化, 2018, 17(1): 1-5.
|
[4]
|
陈楠. 罗沙司他在慢性肾脏病患者肾性贫血治疗中的应用[J]. 中华内科杂志, 2019, 58(12): 919-920.
|
[5]
|
张倩, 巴应贵. 肾性贫血发生机制的研究现状[J]. 临床医学进展, 2021, 11(5): 2251-2256.
https://doi.org/10.12677/ACM.2021.115324
|
[6]
|
Souma, T., Norio, S. and Yamamoto, M. (2015) Renal Eryth-ropoietin-Producing Cells in Health and Disease. Frontiers in Physiology, 6, Article 167. https://doi.org/10.3389/fphys.2015.00167
|
[7]
|
李伟英, 陈崴. 肾性贫血铁代谢指标的评估、判读及应用[J]. 中国实用内科杂志, 2020, 40(12): 1010-1014.
|
[8]
|
Rodriguez, R., Jung, C.L., Gabayan, V., Deng, J.C., Ganz, T., Nemeth, E., Bulut, Y. and Roy, C.R. (2014) Hepcidin Induction by Pathogens and Pathogen-Derived Molecules Is Strongly Dependent on Interleukin-6. Infection & Immunity, 82, 745-752. https://doi.org/10.1128/IAI.00983-13
|
[9]
|
Kautz, L., Jung, G., Valore, E.V., Rivella, S., Nemeth, E. and Ganz, T. (2014) Identification of Erythroferrone as an Erythroid Regulator of Iron Metabolism. Nature Genetics, 46, 678-684. https://doi.org/10.1038/ng.2996
|
[10]
|
谭娉婵, 罗良海, 邓卫, 谭晓军. 罗沙司他与重组人促红细胞生成素治疗血液透析肾性贫血临床疗效的比较研究[J]. 临床合理用药杂志, 2021, 14(18): 5-8.
|
[11]
|
白瑞, 张蕾. 低氧诱导因子脯氨酰羟化酶抑制剂治疗肾性贫血的研究进展[J]. 实用医药杂志, 2021, 38(3): 272-276.
|
[12]
|
郝传明, 李菁. 脯氨酰羟化酶抑制剂治疗肾性贫血: 全新途径, 全新挑战[J]. 肾脏病与透析肾移植杂志, 2021, 30(3): 203-204.
|
[13]
|
Liu, Q., Davidoff, O., Niss, N. and Haase, V.H. (2012) Hypoxia-Inducible Factor Regulates Hepcidin via Erythropoietin-Induced Erythropoiesis. Journal of Clinical Investigation, 122, 4635-4644. https://doi.org/10.1172/JCI63924
|
[14]
|
徐巧玲, 朱翊, 何笑荣, 张田, 金鹏飞. 罗沙司他治疗肾性贫血安全性的研究进展[J]. 中国医院用药评价与分析, 2022, 22(6): 761-764+768.
|
[15]
|
徐丹, 冯霞, 钟询龙, 王若伦. 罗沙司他治疗肾性贫血效果的影响因素分析[J]. 中国医院药学杂志, 2022, 42(7): 732-735.
|
[16]
|
Provenzano, R., Tumlin, J., Zabaneh, R., Chou, J., Hemmerich, S., Neff, T.B. and Yu, K.H.P. (2020) Oral Hypoxia-Inducible Factor Prolyl Hy-droxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. The Journal of Clinical Pharma-cology, 60, 1432-1440. https://doi.org/10.1002/jcph.1648
|
[17]
|
Dhillon, S. (2019) Roxadustat: First Global Ap-proval. Drugs, 79, 563-572.
https://doi.org/10.1007/s40265-019-01077-1
|
[18]
|
Provenzano, R., Besarab, A., Wright, S., Dua, S., Zeig, S., Nguyen, P., Poole, L., Saikali, K.G., Saha, G. and Hemmerich, S. (2016) Roxadustat (FG-4592) versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. American Journal of Kidney Diseases, 67, 912-924. https://doi.org/10.1053/j.ajkd.2015.12.020
|
[19]
|
Vaziri, N.D. and Zhou, X.J. (2009) Potential Mechanisms of Adverse Outcomes in Trials of Anemia Correction with Erythropoietin in Chronic Kidney Disease. Nephrology Dialysis Transplantation, 24, 1082-1088.
https://doi.org/10.1093/ndt/gfn601
|
[20]
|
李绵绵, 李芳, 余玲玲, 陈小剑. 新型网织红细胞参数在贫血早期诊断中的价值[J]. 中国卫生检验杂志, 2019, 29(11): 1289-1291.
|
[21]
|
李小龙, 陶洪群, 王薇薇, 徐斐, 黄小芳, 王赛芳, 刘欢乐, 王金果, 刘晖. 网织红细胞血红蛋白含量在缺铁性贫血诊断治疗中的价值[J]. 中华血液学杂志, 2015, 36(8): 695-697.
|
[22]
|
Yaribeygi, H., Butler, A.E., Barreto, G.E. and Sahebkar, A. (2019) Antioxidative Potential of Antidiabetic Agents: A Possible Protective Mechanism against Vascular Complications in Diabetic Patients. Journal of Cellular Physiology, 234, 2436-2446. https://doi.org/10.1002/jcp.27278
|
[23]
|
双淑贞. 促红细胞生成素对糖尿病肾性贫血患者网织红细胞参数的影响[J]. 当代医学, 2016, 22(31): 145-146.
|
[24]
|
夏坚明, 徐玢, 蒋伟光. 促红细胞生成素治疗糖尿病肾性贫血的网织红细胞参数的变化观察[J]. 中国误诊学杂志, 2008, 8(1): 35-36.
|
[25]
|
Ogawa, C., Tsuchiya, K., Tomosugi, N. and Maeda, K. (2020) A Hypoxia-Inducible Factor Stabilizer Improves Hematopoiesis and Iron Metabolism Early after Administration to Treat Anemia in Hemodialysis Patients. International Journal of Molecular Sciences, 21, Article 7153. https://doi.org/10.3390/ijms21197153
|